Videos

Longitudinal trends in hospitalization rates in patients with later-onset SMA (SMA) treated with nusinersen up to 4.5 years are discussed. Results from the CHERISH and SHINE studies are discussed.

Delving into the realm of refractory polymyalgia rheumatica, Robert Spiera, M.D., discusses the potential inclusion of sarilumab in revised guidelines. He addresses payer concerns regarding prior authorization while emphasizing the importance of ensuring appropriate patient access through evidence-based approaches.

Further discussion of the SHINE study explores characteristics unique to the trial's patient population.

Socioeconomic factors impacting patients seeking infertility treatment are highlighted.

Robert Spiera, M.D., highlights the impact of sustained remission on polymyalgia rheumatica treatment, emphasizing improvements in quality of life and steroid-related effects.

Robert Spiera, M.D., explores sarilumab’s impact on polymyalgia rheumatica, emphasizing reduced steroid use and enhanced quality of life.

A medical expert underscores the significance of infertility treatment coverage.

This study explores the background and rationale behind utilizing nusinersen for the treatment of Spinal Muscular Atrophy (SMA), shedding light on the critical need for the SHINE study. Delving into the characteristics of the patient population involved, the research aims to deepen our understanding of the therapeutic potential of nusinersen in addressing SMA, a debilitating genetic disorder.

Robert Spiera, M.D., reviews key patient characteristics from the study of sarilumab in refractory polymyalgia rheumatica.

Sean Tipton delivers an expert perspective on harnessing fertility benefits.

Dr. Chervenak evaluates access to care in the current health care system for patients seeking treatment in reproductive medicine.

Robert Spiera, M.D., discusses the SAPHYR trial, assessing sarilumab’s efficacy in treating refractory polymyalgia rheumatica.

A key opinion leader discusses trending and breakthrough treatment strategies for patients seeking infertility treatment.

Dana McCormick, R.Ph., and Robert Spiera, M.D., delve into the SAPHYR trial, discussing sarilumab’s role in managing polymyalgia rheumatica relapse during glucocorticoid tapers.

Joseph Chervenak, MD, MBA, begins a discussion surrounding innovative processes in reproductive medicine.

Drs. Owens and Rosmarin discuss payer and provider perspectives from the TRuE-V studies.

The limitations from the TRuE-V studies are analyzed.

By identifying patients with glaucoma who are socially vulnerable, clinicians might intervene sooner and prevent the worsening of visual impairment, he said.

Key adverse events from the TRuE-V studies are highlighted.

Dr. Rosmarin discusses the efficacy data from the TRuE-V long-term extension study.

A medical expert highlights a new FDA-approved medication as a key treatment in Demodex blepharitis.

The study design for the TRuE-V long-term extension study is discussed.

Therapies such as tee tree oil and other OTC agents are evaluated in the management of Demodex blepharitis.

The key safety and efficacy data of the TRuE-V studies are discussed.

Dr Starr provides considerations for navigating diagnostic challenges related to Demodex blepharitis.

Chesahna Kindred, M.D., MBA, FAAD, reviews the vitiligo support groups recommended for patients.

Renata Block, PA-C, and Gary M. Owens, M.D., explore the access considerations for patients with vitiligo in special populations and review resources that clinicians and payers can share with patients with vitiligo.

Chesahna Kindred, M.D., MBA, FAAD, examines how treatment can affect the quality of life in patients with vitiligo.

Drs. Owens and Rosmarin discuss an overview of the TRuE-V studies and unmet needs in vitiligo.